Ontology highlight
ABSTRACT:
SUBMITTER: Nghiemphu PL
PROVIDER: S-EPMC5756101 | biostudies-other | 2018 Jan
REPOSITORIES: biostudies-other
Nghiemphu Phioanh Leia PL Ebiana Victoria Asuquo VA Wen Patrick P Gilbert Mark M Abrey Lauren E LE Lieberman F F DeAngelis Lisa M LM Robins H Ian HI Yung W K Alfred WKA Chang Susan S Drappatz Jan J Mehta Minesh P MP Levin Victor A VA Aldape Kenneth K Dancey Janet E JE Wright J J JJ Prados Michael M Kuhn John J Cloughesy Timothy F TF
Journal of neuro-oncology 20171007 1
Recurrent glioblastoma (GBM) has a very low 6-month progression free survival (PFS) with currently available treatments. Combination chemotherapy to target multiple cell signaling pathways is currently being investigated in order to improve prognosis for recurrent disease. The purpose of this phase I study was to determine the maximum tolerated dose (MTD) for the combination of tipifarnib and sorafenib for the treatment of recurrent GBM. Patients with pathologically proven WHO grade IV GBM and r ...[more]